Latest news
Hear the Word : World Hearing Day 2021
Each year on March 3rd, the community celebrates World Hearing Day, an annual event organized by the World Health Organization to raise awareness around hearing disorders. This year, CILcare is pleased to be joined by actors and experts from all over the hearing field...
CILcare is attending ARO’s 2021 Midwinter Meeting!
CILcare is pleased to announce its participation at ARO's 2021 Midwinter Meeting, an event that gathers the most innovative actors in the hearing field. Workshop : Translating Pre-Clinical Findings Into Successful Clinical TrialsCILcare is pleased to announce its...
Mathieu Schué joins CILcare as Project Director of Drug Development and Translational Research
Montpellier, January 14th, 2021: CILcare, the world leading CRO specialized in the field of Hearing, recently had the immense pleasure of welcoming Dr. Mathieu Schué to the team as Project Director of Drug Development & Translational Research. In this role,...

Pharma / Biotech

Medtech

Nutraceutical

Veterinary
CILcare, the world leading CRO dedicating to ear disorders
Because research & development in hearing is as fascinating as it is complex, preclinical studies require perfectly accurate and reproducible measures using state-of-the-art technology in acoustics and electrophysiology. CILcare’s core values lie in our validated and highly robust animal models, enabling us to deliver consistent and valid results.
Drawing from an extensive industrial background, we guide our partners from target identification to IND, and work closely together to advance auditory research and reach a common goal: serve patient population who need our help the most.
CILcare proposes services to develop innovative solutions for hearing loss, tinnitus, otitis, and ototoxicity

Drugs to treat Hearing Loss and Tinnitus

Drugs and Medical Devices to treat Otitis

Medications safe for the ear (absence of ototoxicity)

Regenerative Therapies: Gene and Cell Therapies

Implantable Drug Delivery Devices and Imaging
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 750 billion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.